Inovio Pharmaceuticals (FRA:GBM) Moat Score: 3/10 (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:GBM Inovio Pharmaceuticals Inc FRA:GBM
35 GF Score
Price €0.74
GF Value €0.24
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Inovio Pharmaceuticals Moat Score?

Inovio Pharmaceuticals FRA:GBM -14.59% 35 Moat Score is 3 as of Jul. 31, 2026. GuruFocus rates FRA:GBM with a GF Score™ of 35/100 and a GF Value™ of €0.24 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,394 Biotechnology companies, Inovio Pharmaceuticals ranks better than 75.61% on this metric.

Inovio Pharmaceuticals has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Inovio Pharmaceuticals has No Moat: Inovio Pharmaceuticals Inc has limited market share and lacks significant regulatory barriers or exclusive licenses. While it may have some intellectual property, it does not translate into strong customer loyalty or pricing power. The company's innovation efforts are not yet impactful enough to establish a durable moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Inovio Pharmaceuticals might have No Moat - Very weak/transient advantages.

Inovio Pharmaceuticals  (FRA:GBM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Inovio Pharmaceuticals Moat Score Related Terms

FRA:GBM vs TELO, ELTX, ALPS: Moat Score Comparison

For the Biotechnology subindustry, Inovio Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inovio Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Moat Score falls into.


FRA:GBM
35GF Score
Inovio Pharmaceuticals Inc FRA:GBM
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Inovio Pharmaceuticals (FRA:GBM) has a Moat Score of 3 as of Jul. 31, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Inovio Pharmaceuticals ranks #340 out of 1394 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Inovio Pharmaceuticals' Moat Score too high?
Inovio Pharmaceuticals' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Inovio Pharmaceuticals' value of 3 is 50% above this industry median. Based on the distribution chart, Inovio Pharmaceuticals ranks #340 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Inovio Pharmaceuticals has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' Moat Score compare to TELO and ELTX?
According to the Biotechnology industry distribution chart, Inovio Pharmaceuticals ranks #340 out of 1394 companies for Moat Score. This places Inovio Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Inovio Pharmaceuticals' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inovio Pharmaceuticals's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inovio Pharmaceuticals's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (FRA:GBM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.24, compared to a current price of €0.74 — trading 209.8% above its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Inovio Pharmaceuticals' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Inovio Pharmaceuticals (FRA:GBM), the current Moat Score is 3 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inovio Pharmaceuticals (FRA:GBM) Overvalued in 2026?

Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued. The current stock price of €0.74 is trading 209.8% above its estimated GF Value™ of €0.24. GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:GBM:

  • Moat Score: 3
  • GF Value™: €0.24 vs. price of €0.74 (209.8% above fair value)
  • GF Score™: 35/100 with 4 warning signs
  • Industry Position: 50% above the Biotechnology median (#340 of 1394)

No single metric tells the full story. See the FRA:GBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inovio Pharmaceuticals Business Description

Address 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
35GF Score

Get the complete analysis for FRA:GBM

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.74
Price
€0.24
GF Value